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Abstract
Dengue represents an increasingly important public health challenge in Puerto Rico, with recent 
epidemics in 2007, 2010, and 2012–2013. Although recent advances in dengue vaccine 
development offer hope for primary prevention, the role of health professionals in the diagnosis 
and management of dengue patients is paramount. Case definitions for dengue, dengue with 
warning signs, and severe dengue provide a framework to guide clinical decision-making. 
Furthermore, the differentiation between dengue and other acute febrile illnesses, such as 
leptospirosis and chikungunya, is necessary for the appropriate diagnosis and management of 
cases. An understanding of dengue epidemiology and surveillance in Puerto Rico provides context 
for clinicians in epidemic and non-epidemic periods. This review aims to improve health 
professionals’ ability to diagnose dengue, and as highlight the relevance of recent advances in 
dengue prevention and management in Puerto Rico.
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Dengue represents an increasingly important global health challenge, as recent estimates 
suggest that nearly 2.5 billion people worldwide are at risk for infection (1) and 390 million 
infections occurred in 2010 (2). The 4 dengue virus-types (DENV-1–4) that cause dengue 
are single-stranded, positive-sense RNA viruses of the family Flaviviridae. Aedes aegypti 
and Ae. albopictus mosquitoes are endemic throughout the tropics and subtropics and serve 
as the primary vector for DENV transmission. DENV infection can result in a range of 
outcomes, from asymptomatic infection, to self-limited acute febrile illness (AFI), to 
potentially fatal severe dengue (1).
In 2009, the World Health Organization (WHO) revised the clinical classification of dengue, 
reclassifying dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome 
Address correspondence to: Tyler M. Sharp, PhD, Centers for Disease Control and Prevention - Dengue Branch, 1324 Calle Canada, 
San Juan, PR 00920. tsharp@cdc.gov. 
The authors have no conflicts of interest to disclose.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or CDC.
HHS Public Access
Author manuscript
P R Health Sci J. Author manuscript; available in PMC 2016 June 01.
Published in final edited form as:













(DSS) (3) as dengue, dengue with warning signs, and severe dengue (1). A major impetus 
for this change was the observation that many life-threatening dengue cases did not meet the 
definition of either DHF or DSS, and the identification of clinical signs and symptoms 
present in some dengue cases were positively associated with the development of more 
severe illness (4, 5). Dengue is characterized by fever, anorexia, rash, aches and pains, and 
leucopenia (1). Warning signs that signal development of severe dengue include abdominal 
pain, persistent vomiting, mucosal bleed, hepatomegaly greater than 2 centimeters, clinical 
fluid accumulation, lethargy or restlessness, and hemoconcentration concurrent with a rapid 
decrease in platelet count. Severe dengue is characterized by plasma leakage that may lead 
to shock, severe bleeding, severe organ impairment or any combination thereof.
In Puerto Rico, clinical suspicion of dengue should be followed by the collection of a serum 
specimen and completion of a Dengue Case Investigation Form (available at www.cdc.gov/
dengue/resources/dengueCaseReports/DCIF_English.pdf or www.cdc.gov/dengue/
resources/dengueCaseReports/DCIF_Spanish.pdf) to enable case reporting and diagnostic 
testing by either reverse transcriptase-polymerase chain reaction (RT-PCR) to directly detect 
viral genome and/or IgM antibody-capture enzyme-linked immunosorbent assay (MAC-
ELISA) to detect anti-DENV immunoglobulin M (IgM) antibodies. Although primary 
DENV infection confers lifelong immunity to the infecting DENV type, subsequent 
infection with another DENV type confers a slight but statistically significant increased risk 
of developing more severe illness (6).
Currently, no vaccine or anti-viral drug is available to prevent or treat dengue, although 
several vaccine candidates are in clinical trials (7, 8). The mainstay for treatment of dengue 
is therefore supportive care, which can reduce the case-fatality rate in hospitalized patients 
from approximately 10% to less than 0.5% (1, 9). The clinical management of patients 
depends on recognition of the 3 phases of dengue: the febrile phase, critical phase, and 
recovery phase. During the febrile phase, maintaining proper hydration and vigilance for the 
warning signs of severe dengue are important. Defervescence, typically 3–7 days after 
illness onset, defines the start of the critical phase, which typically lasts 24–48 hours. 
Hemoconcentration may also occur as a result of plasma leakage in the critical phase, in 
which case judicious use of intravenous fluids and close monitoring of clinical status are 
needed to avert shock, organ impairment, and unnecessary morbidity. Corticosteroids, 
though once thought to benefit dengue patients, have not been shown to decrease mortality 
or morbidity due to dengue and in fact may result in increased morbidity due to 
immunosuppression and/ or the increased risk of gastrointestinal bleeding (10, 11). The 
recovery phase reflects a return to normal capillary permeability, although continued 
monitoring of fluid status is important to avoid fluid overload. Detailed patient management 
protocols and best practice guidelines elaborate on the appropriate clinical management of 
patients suspected of having or with confirmed dengue (Figure 1) (1).
Dengue epidemiology
Outbreaks of dengue-like illnesses were first reported in the 1600s and have been 
consistently reported from various regions of the tropics for more than a century. Although 
the Americas experienced a reprieve from dengue in the 1950s and 1960s following an 
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extensive Aedes aegypti elimination program by the Pan American Health Organization 
(PAHO) (12), the recent resurgence of dengue in the region reflects global trends (1, 13, 14) 
in urbanization and migration and demonstrates that current prevention measures are 
inadequate (15,16). The number of dengue cases reported to WHO nearly doubled between 
the 1990s and the early 2000s (17), and in 2010 an estimated 96 million dengue cases 
occurred worldwide (2). The need to evaluate the economic impact of dengue and novel 
prevention methods, such as vaccines, underscores the importance of maintaining disease 
surveillance to better understand changes in dengue epidemiology.
The seasonal and cyclical natures of dengue are due in part to environmental influences, in 
particular rainfall, temperature (18), and weather indices such as El Niño Southern 
Oscillation (19), all of which affect the proportion of individuals in the population that are 
susceptible to the DENV types in circulation. DENV transmission via the vector Ae. aegypti 
tends to increase as conditions favor the reproduction of mosquitos. Nevertheless, a recent 
review of the literature emphasizes the complex interactions between environment, the 
mosquito vector, and host factors in the propagation of DENV, cautioning that the current 
methods, which rely on environmental models to predict the spread of dengue, have 
limitations (20).
Dengue in Puerto Rico
The first reported dengue outbreak in Latin America occurred in the early 1600s on the 
Caribbean island of Martinique (21). Similar outbreaks of a dengue-like illness spread 
throughout Latin America over the subsequent 3 centuries (21). In Puerto Rico, outbreaks of 
a dengue-like illness were reported in 1918 (22) and in 1945 (23), DENV-2 was isolated 
during an outbreak in 1963–1964 and endemicity of dengue was documented soon after 
(24). The introduction of additional DENV types was documented in outbreaks in the 1970s 
and 1980s, and in 1998 an outbreak occurred in which all 4 DENV types were circulating 
(25). Dengue epidemics occurred most recently in Puerto Rico in 2007 (26), 2010 (27), and 
2012–2013 (PRDH, unpublished data) (Figure 2).
Dengue epidemiology in Puerto Rico during epidemic and non-epidemic years consistently 
reveals a disproportionate burden of disease for individuals aged 10–19 years, followed by 
younger children and infants; nonetheless, adults consistently represent roughly one-half of 
all reported cases (25–27). There have been no consistent differences in the incidence of 
dengue by sex or race. In 2007, a total of 10,508 suspected cases and 44 deaths were 
reported; however, only one-third of the suspected cases and 11 of the fatal cases had 
laboratory evidence of DENV infection. Moreover, among all the laboratory-positive 
dengue cases identified, the percentage of individuals that had been previously infected with 
a DENV was greater than 75% (26). A separate investigation regarding the 11 lab-confirmed 
deaths revealed that less than half received a clinical diagnosis of dengue, more than half 
were given corticosteroids, and none were managed according to the WHO guidelines (28). 
Subsequently, the 2010 epidemic documented nearly 27,000 suspected cases and 128 fatal 
cases, of which half and one-third were laboratory confirmed, respectively (27). Similar to 
the 2007 epidemic, approximately 80% of the dengue cases had been previously infected 
with a DENV. The 2007 and 2010 epidemics illustrated critical lessons about dengue 
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epidemiology in Puerto Rico and revealed several aspects of dengue clinical case 
management in need of improvement (e.g., use of non-isotonic intravenous saline, frequency 
of vital sign monitoring, administration of corticosteroids).
Dengue surveillance in Puerto Rico
Dengue in Puerto Rico is monitored with the Passive Dengue Surveillance System (PDSS), 
which was established in the late 1960s (29). PDSS was, for several decades, a collaborative 
surveillance system co-operated by Puerto Rico Department of Health (PRDH) and the 
Centers for Disease Control and Prevention-Dengue Branch (CDC-DB) located in San Juan. 
However, since 2012, the PDSS has been operated primarily by PRDH. A general overview 
of PDSS spans from the initial interfacing of a patient with the health care system to the 
reporting of a suspected dengue case to the public health response (Figure 3). Overall goals 
of dengue surveillance1 include the early detection of increased incidence to enable early 
intervention, measurement of disease burden, evaluation of programs to prevent and control 
dengue, and facilitation of appropriate resource distribution.
An evaluation of PDSS from 2009–2011, guided by the 9 attributes of public health 
surveillance (30), identified strength in the utility, flexibility, and stability of the system; 
however, timeliness, sensitivity, and acceptability represented attributes to be improved 
(CDC-DB, unpublished data). Data quality, positive predictive value, and simplicity of the 
surveillance system were considered to be acceptable. The total times for specimens to be 
transported (Figure 4), processed, tested, and reported back to clinicians were 10 days in an 
epidemic period and 15 days during a non-epidemic period, thus reducing the clinical utility 
of diagnostic testing for health care providers. Nevertheless, the primary purpose of PDSS is 
to inform public health decision-making and not to produce diagnostic test results. The 
stability of PDSS over the past several decades contributes to its utility in monitoring 
dengue epidemiology and in directing public health action in Puerto Rico.
An inherent limitation of passive surveillance is the difficulty of measuring the true burden 
of disease. A meta-analysis of surveillance systems throughout Latin America and Southeast 
Asia revealed significant underreporting of dengue cases: from 3–9 symptomatic cases not 
being reported for each case that was reported (31). Studies in Puerto Rico in the 1990s 
estimated that for each case of dengue reported to the PDSS, 10–27 additional cases were 
not reported (32, 33). Although recent estimates of underreporting are needed, much 
anecdotal evidence suggests that PDSS is biased towards hospitalized cases (CDC-DB, 
unpublished data).
To improve surveillance, a pilot enhanced surveillance system was implemented in 2005 in 
Patillas to encourage health care providers to report suspected cases (34). In 2009, the WHO 
recommended the addition of sentinel surveillance systems to complement passive 
surveillance (1, 31). To meet this need, in 2012 CDC-DB established the Sentinel Enhanced 
Dengue Surveillance System (SEDSS) in Ponce, and later expanded it to sites in Guayama 
and Carolina (35). A major utility of the SEDSS sites includes the ability to determine 
baseline levels of dengue, which will be needed to evaluate the efficacy of a dengue vaccine 
and more accurately quantitate the burden of all clinically-apparent dengue cases. This will 
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enable a better understanding and evaluation of interventions that are implemented to 
control dengue in Puerto Rico.
Dengue diagnosis
Dengue surveillance systems in Puerto Rico, both passive and enhanced, depend on accurate 
diagnostic testing to identify DENV-infected individuals; however, the time between 
specimen collection and laboratory confirmation frequently approaches 2 or more weeks due 
primarily to delays in specimen transport and in the subsequent receipt of reports containing 
diagnostic test results (CDC-DB, unpublished data). Consequently, surveillance-based 
diagnostic testing provides minimal clinical utility to the health care provider. Rapid 
diagnostic tests, in conjunction with a clinical diagnosis of probable dengue, promise greater 
utility in population-based surveillance for dengue, particularly in resource-poor settings in 
which instrument-independent laboratory diagnostics are necessary (36, 37). Despite this, 
rapid diagnostic tests have not yet been demonstrated to be sufficiently reliable to enable 
individual patient diagnosis and management. Alternatively, highly sensitive and specific 
laboratory-based diagnostic tests are now available that can accurately diagnose dengue 
patients using a single serum specimen. Both molecular (38) and serologic (39) diagnostic 
tests that have been approved by the FDA are available in Puerto Rico at PRDH and CDC-
DB, and currently all submitted specimens are tested for evidence of DENV infection. 
However, until these or other tests are available at centralized locations in hospitals and 
clinics, the clinical diagnosis made by the health care provider will continue to be the 
primary method used to diagnose and, consequently, treat suspected dengue cases.
The clinical diagnosis of dengue in endemic areas is often complicated by the myriad of 
other endemic acute febrile illnesses (AFIs) and the dynamic epidemiologic trends of such 
diseases. Influenza, leptospirosis, an array of respiratory illnesses, and various other 
bacterial infections often muddle the picture of a non-differentiated AFI, which may be 
misdiagnosed as dengue during dengue epidemics (40). The aforementioned WHO criteria 
for dengue demonstrate considerable overlap of the non-specific symptoms with those of 
other AFIs. Furthermore, the recent emergence of chikungunya in Puerto Rico (41), which 
has a clinical presentation similar to that of dengue and is also transmitted by Aedes species 
mosquitos (42), further complicates the identification of dengue patients.
Historically, epidemiologic studies focus primarily on differentiating laboratory-positive 
dengue patients from dengue-negative patients in regions with endemic dengue. One 
systematic review (43) and studies in Puerto Rico (44) observed associations between 
dengue cases and decreased platelets and white blood cell count in addition to observing an 
increased proportion of patients with myalgia, rash, and hemorrhagic signs. Specific 
comparisons between patients with dengue or influenza revealed high proportions of rash, 
hemorrhagic signs, and positive tourniquet test, as well as pronounced thrombocytopenia 
and leukopenia, among dengue patients (45). The scientific literature regarding the clinical 
manifestations of dengue, though varied in the development of predictive models and likely 
influenced by the circulation of different DENV types, provides a framework from which to 
evaluate the utility of clinical diagnoses and improve the timeliness of diagnosis.
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Advances in dengue prevention
In 2003, the Pan American Health Organization (PAHO) developed the Integrated 
Management Strategy for Dengue Prevention and Control (Patio Limpio), and most 
countries in the region adopted this approach; however, the impact of this program has since 
been shown to be minimal (21). The lack of effective approaches in terms of the primary 
prevention of dengue (e.g., a dengue vaccine, sustainable and effective vector control 
methods) therefore demonstrates the importance of secondary prevention (e.g., disease 
surveillance, clinical diagnosis, patient management) in mitigating the morbidity and 
mortality associated with dengue.
An example of this is that after noting the sub-optimal management of fatal dengue cases 
during the 2007 epidemic in Puerto Rico (46), medical epidemiologists from CDC-DB 
utilized the 2009 WHO Dengue Guidelines (1) to design a 4-hour clinical training course for 
physicians, that outlined the recommended management of dengue patients. When the 2010 
epidemic was growing in magnitude and fatal cases began to be reported, the Secretary of 
Health of Puerto Rico mandated that all clinicians who see dengue patients take the course, 
and more than 11,000 clinicians were ultimately trained. An evaluation of clinical practices 
in 2009 compared to 2011 demonstrated significant increases in adherence to the 
recommended clinical practices, such as the use of isotonic intravenous saline, frequency of 
monitoring vital signs, and avoidance of corticosteroid administration (CDC-DB, 
unpublished data). This course was subsequently developed into an online training 
(available at www.cdc.gov/dengue/training/cme.html) that clinicians can take to receive 
continuing medical education credit. Thus, although an effective and sustainable approach to 
the primary prevention of dengue is not yet available, improvements in the clinical 
management of hospitalized dengue patients can reduce the case-fatality rate to below 0.5% 
(9).
Despite the recognition of dengue as a neglected tropical disease, considerable attention by 
global, regional, and local stakeholders has produced invaluable resources to guide 
preventive efforts. The most recent initiative by the WHO focuses on diagnosis and case 
management, integrated surveillance and outbreak preparedness, sustainable vector control, 
future vaccine implementation, and basic operational and implementation research as key 
components to reduce dengue mortality by 50% and morbidity by 25% by 2020 (47).
Recent advances in dengue vaccine development offer hope for control and prevention. One 
vaccine candidate reported an overall efficacy of 56%, with an excellent safety profile from 
a phase III trial in Southeast Asia (48), though sub-optimal protection against illness due to 
infection with DENV-2 was consistent with previous studies (8). Nevertheless, the potential 
to prevent dengue, especially severe cases (49), with this vaccine and others (50) in 
development underscores the importance of accurate clinical diagnosis and surveillance to 
measure the impact of those vaccines. Therefore, until a vaccine or other sustainable and 
effective approach to dengue control becomes available, health professionals will continue 
to play the most critical role in the clinical management of individuals with dengue or other 
AFIs in Puerto Rico.
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Schematic of World Health Organization guidelines (1) for clinical management of patients 
suspected of having dengue.
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Suspected dengue cases reported to the passive dengue surveillance system during 1986–
2013. The dotted horizontal line indicates the epidemic threshold.
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Schematic of how the passive dengue surveillance system (PDSS) operated until 2012. 
PDSS is initiated when a patient seeks medical care, following which the patient’s medical 
provider suspects dengue as a cause of the patient’s illness. When this occurs, the clinician 
orders a blood specimen be collected from the patient and the Dengue Case Investigation 
Form (DCIF) is completed; both the specimen and DCIF are transported by the Puerto Rico 
Department of Health (PRDH) to the Centers for Disease Control and Prevention, Dengue 
Branch (CDC-DB). Specimens are tested, and the patient information from the DCIF is 
entered into a database at the CDC-DB. Diagnostic test results are sent to the health care 
provider who reported the case, who then relays the results to the patient and, if necessary, 
requests that the patient return to provide a convalescent serum specimen. Patient 
demographic information is compiled into weekly reports that CDC-DB and PRDH 
disseminate to stakeholders and the public via weekly reports. PRDH uses data from these 
reports to direct response activities in the areas most affected by dengue. After 2012, all 
activities indicated as being conducted by CDC-DB began instead to be conducted by 
PRDH.
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Median number of days needed for a specimen to arrive at Centers for Disease Control and 
Prevention, Dengue Branch (CDC-DB), according to a particular patient’s municipality of 
residence in 2009 (A), 2010 (B) and 2011 (C). Light green, dark green, yellow, and red 
regions indicate municipalities with an average transport time of 0–2, 3–4, 5–7, and >8 days, 
respectively.
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